publication date: Feb. 28, 2017

NCI CTEP-Approved Trials for February

The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month. For further information, contact the principal investigator listed.


Phase I                10002

A Phase I Study of Indenoisoquinoline LMP744 in Adults with Relapsed Solid Tumors and Lymphomas

National Cancer Institute Developmental Therapeutics Clinic

O’Sullivan Coyne, Geraldine

(301) 402-9122


Phase II               AALL162

A Phase 2 Study of Inotuzumab Ozogamicin (NSC# 772518, IND#TBD) in Children and Young Adults with Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL)

Children’s Oncology Group

O’Brien, Maureen Megan

(513) 803-1678


Phase II               EAF151

Change in Relative Cerebral Blood Volume as a Biomarker for Early Response to Bevacizumab in Patients with Recurrent Glioblastoma

ECOG-ACRIN Cancer Research Group

Boxerman, Jerrold L.

(401) 444-5184


Phase II               ECOG-ACRIN-EA9131

A Simplified Patient Care Strategy to Decrease Early Deaths in Acute Promyelocytic Leukemia (APL)

ECOG-ACRIN Cancer Research Group

Jillella, Anand P.

(404) 778-3510


Phase II               S1400G

A Phase II Study of Talazoparib (BMN 673) in … Continue reading CCL Feb 2017 – NCI CTEP-Approved Trials for February

To access this members-only content, please log in.
If you're not a subscriber why not join today?
If you believe you should be able to view this area but cannot log in, then please contact us and we will try to rectify this issue as soon as possible.
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2017 The Cancer Letter Inc.